Smith & Nephew SNATS Inc
$ 31.32
3.23%
09 Jun - close price
- Market Cap 12,877,062,000 USD
- Current Price $ 31.32
- High / Low $ 31.40 / 30.85
- Stock P/E 21.22
- Book Value 2.49
- EPS 1.43
- Next Earning Report 2026-08-04
- Dividend Per Share $0.39
- Dividend Yield 2.58 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.12 %
- 52 Week High 37.90
- 52 Week Low 27.75
About
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Analyst Target Price
$34.99
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-02 | 2025-11-06 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-10-31 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 0 | 0.38 | 0 | 0.33 | 0 | 0.23 | 0 | 0.756 | 0 | 1.31 | 0 | 0.35 |
| Estimated EPS | 0 | 1.12 | 0 | 1.03 | 0 | 0.97 | 0 | 0.93 | 0 | 0.96 | 0 | 0.81 |
| Surprise | 0 | -0.74 | 0 | -0.7 | 0 | -0.74 | 0 | -0.174 | 0 | 0.35 | 0 | -0.46 |
| Surprise Percentage | None% | -66.0714% | None% | -67.9612% | None% | -76.2887% | None% | -18.7097% | None% | 36.4583% | None% | -56.7901% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| May 2026 | Nov 2025 | May 2025 | Nov 2024 | May 2024 | Nov 2023 | May 2023 | Oct 2022 | May 2022 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-27 | 2025-11-07 | 2025-05-28 | 2024-11-08 | 2024-05-22 | 2023-11-01 | 2023-05-17 | 2022-10-26 | 2022-05-11 | None |
| Amount | $0.482 | $0.3 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNN
2026-06-09 08:40:31
Smith & Nephew plc (SNN) published a slide deck in connection with a shareholder/analyst call. The article was written by SA Transcripts, Seeking Alpha's team responsible for transcript-related projects, including thousands of quarterly earnings calls. The purpose of the profile is to share new transcript developments with readers.
2026-06-08 17:39:07
Smith+Nephew has announced the completion of the first clinical cases using its next-generation CORIâ—ŠXT Handheld Robotics Platform for both knee and shoulder arthroplasty. This platform is designed to provide robotic assistance while maintaining surgeon control and workflow efficiency, suitable for various orthopedic needs in both hospitals and ambulatory surgical centers. The initial cases were successfully performed at Duke Health, North Valley Surgery Center, and NYU Langone Health, marking a significant step in the broader clinical introduction of the technology.
2026-06-06 01:10:56
Cevian Capital II GP LTD has significantly increased its stake in Smith & Nephew PLC by acquiring an additional 9,584,693 shares at $29.48 each, raising its total holdings to 101,046,788 shares. This strategic move, which increased Cevian Capital's portfolio allocation to Smith & Nephew by 8.31%, indicates strong confidence in the medical device company's growth potential. Smith & Nephew, a UK-based medical device manufacturer with a $12.9 billion market cap, is considered fairly valued with good outperformance potential, supported by robust financial metrics.
2026-06-04 15:39:52
Smith & Nephew plc reported that its CEO and several senior managers acquired American Depositary Shares (ADS) through the company's employee Dividend Re-Investment Plan. These acquisitions, including those by CEO Deepak Nath and other key officers, occurred on June 3, 2026, at a price of $29.8328 per ADS on the New York Stock Exchange, following the 2025 final dividend payment. The transactions were disclosed in accordance with UK Market Abuse Regulation.
2026-06-04 11:39:52
Several senior executives at Smith & Nephew (SNN) have reinvested their 2025 final dividends into company shares through a Dividend Re-Investment Plan. This move, which involved purchases on the London Stock Exchange, increases insider ownership and offers transparency regarding leadership's alignment with shareholders. TipRanks' AI Analyst, Spark, rates SNN as "Outperform" due to improving financial performance and supportive technicals, despite some valuation and near-term headwinds.
2026-06-04 07:39:52
Kepler Cheuvreux has downgraded Smith & Nephew (NYSE:SNN) from a "buy" to a "hold" rating, lowering its price target due to investor focus shifting to revenue growth rather than operational improvements. The firm highlighted that the company's fiscal 2026 guidance requires a significant step-up after a weak first quarter and noted two unresolved headwinds in the U.S. market, seeing limited near-term catalysts for a stock re-rating. Despite this, InvestingPro Tips indicate the company has maintained dividend payments for 50 consecutive years and trades at a low P/E ratio relative to near-term earnings growth.
